234 related articles for article (PubMed ID: 22244151)
1. Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy.
Avery KN; Metcalfe C; Vedhara K; Lane JA; Davis M; Neal DE; Hamdy FC; Donovan JL; Blazeby JM
Eur Urol; 2012 Oct; 62(4):649-55. PubMed ID: 22244151
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study.
Young GJ; Harrison S; Turner EL; Walsh EI; Oliver SE; Ben-Shlomo Y; Evans S; Lane JA; Neal DE; Hamdy FC; Donovan JL; Martin RM; Metcalfe C
BMJ Open; 2017 Oct; 7(10):e017729. PubMed ID: 29084797
[TBL] [Abstract][Full Text] [Related]
3. Deliberative democracy and cancer screening consent: a randomised control trial of the effect of a community jury on men's knowledge about and intentions to participate in PSA screening.
Thomas R; Glasziou P; Rychetnik L; Mackenzie G; Gardiner R; Doust J
BMJ Open; 2014 Dec; 4(12):e005691. PubMed ID: 25539779
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations?
Avery KN; Metcalfe C; Blazeby JM; Lane JA; Neal DE; Hamdy FC; Donovan JL
BJU Int; 2008 Dec; 102(11):1629-33. PubMed ID: 18710456
[TBL] [Abstract][Full Text] [Related]
5. Men's preferences and trade-offs for prostate cancer screening: a discrete choice experiment.
Howard K; Salkeld GP; Patel MI; Mann GJ; Pignone MP
Health Expect; 2015 Dec; 18(6):3123-35. PubMed ID: 25382490
[TBL] [Abstract][Full Text] [Related]
6. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications.
Gershman B; Van Houten HK; Herrin J; Moreira DM; Kim SP; Shah ND; Karnes RJ
Eur Urol; 2017 Jan; 71(1):55-65. PubMed ID: 26995328
[TBL] [Abstract][Full Text] [Related]
7. Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?
Beckmann K; Kinsella N; Olsson H; Wallerstedt Lantz A; Nordstrom T; Aly M; Adolfsson J; Eklund M; Van Hemelrijck M
BMC Urol; 2019 Aug; 19(1):73. PubMed ID: 31383015
[TBL] [Abstract][Full Text] [Related]
8. Informed decision making and prostate specific antigen (PSA) testing for prostate cancer: a randomised controlled trial exploring the impact of a brief patient decision aid on men's knowledge, attitudes and intention to be tested.
Watson E; Hewitson P; Brett J; Bukach C; Evans R; Edwards A; Elwyn G; Cargill A; Austoker J
Patient Educ Couns; 2006 Nov; 63(3):367-79. PubMed ID: 16875796
[TBL] [Abstract][Full Text] [Related]
9. Prostate specific antigen testing in family practice: a cross sectional survey of self-reported rates of and reasons for testing participation and risk disclosure.
Carey M; Bryant J; Yoong SL; Russell G; Barker D; Sanson-Fisher R
BMC Fam Pract; 2013 Dec; 14():186. PubMed ID: 24321004
[TBL] [Abstract][Full Text] [Related]
10. The relationship between prostate cancer knowledge and beliefs and intentions to attend PSA screening among at-risk men.
Hevey D; Pertl M; Thomas K; Maher L; Chuinneagáin SN; Craig A
Patient Educ Couns; 2009 Feb; 74(2):244-9. PubMed ID: 18848753
[TBL] [Abstract][Full Text] [Related]
11. Supporting informed decision making for prostate specific antigen (PSA) testing on the web: an online randomized controlled trial.
Evans R; Joseph-Williams N; Edwards A; Newcombe RG; Wright P; Kinnersley P; Griffiths J; Jones M; Williams J; Grol R; Elwyn G
J Med Internet Res; 2010 Aug; 12(3):e27. PubMed ID: 20693148
[TBL] [Abstract][Full Text] [Related]
12. Prostate specific antigen testing is associated with men's psychological and physical health and their healthcare utilisation in a nationally representative sample: a cross-sectional study.
Flahavan EM; Drummond FJ; Bennett K; Barron TI; Sharp L
BMC Fam Pract; 2014 Jun; 15():121. PubMed ID: 24938184
[TBL] [Abstract][Full Text] [Related]
13. Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
Brindle LA; Oliver SE; Dedman D; Donovan JL; Neal DE; Hamdy FC; Lane JA; Peters TJ
BJU Int; 2006 Oct; 98(4):777-82. PubMed ID: 16978272
[TBL] [Abstract][Full Text] [Related]
14. Decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial.
Avery KN; Blazeby JM; Lane JA; Neal DE; Hamdy FC; Donovan JL
Eur Urol; 2008 Jun; 53(6):1186-93. PubMed ID: 17709169
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
[TBL] [Abstract][Full Text] [Related]
16. Exploring patient perceptions of PSA screening for prostate cancer: risks, effectiveness, and importance.
Smith SD; Birtwhistle R
Can Fam Physician; 2012 Sep; 58(9):e502-7. PubMed ID: 22972741
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing primary care physicians' decision to order prostate-specific antigen (PSA) test for men without prostate cancer.
Hayat Roshanai A; Nordin K; Berglund G
Acta Oncol; 2013 Nov; 52(8):1602-8. PubMed ID: 23421929
[TBL] [Abstract][Full Text] [Related]
18. Medical Maximizing-Minimizing Preferences Predict Responses to Information about Prostate-Specific Antigen Screening.
Scherer LD; Kullgren JT; Caverly T; Scherer AM; Shaffer VA; Fagerlin A; Zikmund-Fisher BJ
Med Decis Making; 2018 Aug; 38(6):708-718. PubMed ID: 29916784
[TBL] [Abstract][Full Text] [Related]
19. A comparison of US and Australian men's values and preferences for PSA screening.
Howard K; Brenner AT; Lewis C; Sheridan S; Crutchfield T; Hawley S; Nielsen ME; Pignone MP
BMC Health Serv Res; 2013 Oct; 13():388. PubMed ID: 24093428
[TBL] [Abstract][Full Text] [Related]
20. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years.
Boegemann M; Stephan C; Cammann H; Vincendeau S; Houlgatte A; Jung K; Blanchet JS; Semjonow A
BJU Int; 2016 Jan; 117(1):72-9. PubMed ID: 25818705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
